Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013:2013:143273.
doi: 10.1155/2013/143273. Epub 2013 Nov 6.

Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients

Gemma Bruera  1 , Katia Cannita, Aldo Victor Giordano, Roberto Vicentini, Corrado Ficorella, Enrico Ricevuto
Affiliations
Clinical Trial

Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients

Gemma Bruera et al. Biomed Res Int. 2013.

Abstract

Four-drug regimens, such as FIr-B/FOx schedule, can improve efficacy of first-line treatment of metastatic colorectal cancer (MCRC) patients. The present study specifically evaluates feasibility of FIr-B/FOx first-line intensive regimen in fit young-elderly MCRC patients, representing approximately 40% of overall MCRC patients. Activity, efficacy, and safety were equivalent to overall MCRC patients, not significantly different according to KRAS genotype. Clinical outcome was significantly prolonged in liver-limited compared to other/multiple metastatic disease. Safety evaluation of the individual young-elderly patient showed that limiting toxicity syndromes (LTS) in multiple sites were significantly increased, compared to LTS in single site, with respect to non-elderly patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Legend Kaplan-Meier survival estimate: (a) overall population, progression-free survival; (b) overall population, overall survival; (c) overall population KRAS wild-type versus KRAS mutant, progression-free survival; (d) overall population KRAS wild-type versus KRAS mutant, overall survival; (e) liver-limited versus other/multiple metastatic sites, progression-free survival; (f) liver-limited versus other/multiple metastatic sites, overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bruera G, Santomaggio A, Cannita K, et al. “Poker” association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer. 2010;10, article 567 - PMC - PubMed
    1. Bruera G, Ricevuto E. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845–52. Expert Opinion on Bioogical Theraphy. 2011;11(6):821–824. - PubMed
    1. Bruera G, Cannita K, Giuliante F, et al. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. Clinical Colorectal Cancer. 2012;11(2):119–126. - PubMed
    1. Ficorella C, Bruera G, Cannita K, et al. Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice. Clinical Colorectal Cancer. 2012;11(4):229–237. - PubMed
    1. Bruera G, Cannita K, Di Giacomo D, et al. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease. BMC Medicine. 2012;10(1, article 135) - PMC - PubMed

Publication types

MeSH terms